← All stocks

Alkermes plc.

ALKS Scheduled selling only
CIK 0001520262 #1047 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$893.46K
$470.59K on a plan · $422.87K straight out of an exercise
Sold at will
$0.00
0 of 4 sales
Net
−$893.46K
$0.00 against sales at will

By person

15 insiders · 4 transactions
52.8×

Richard F. Pops holds 52.8 times base salary in stock. $66.15M of shares against $1.25M in salary for 2025.

Salary from the company's own proxy. The shares are what Richard F. Pops last reported holding, valued at $48.01, the price Ordinary Shares was last bought or sold at on the open market here, on 3 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
$422.87K (1) scheduled
−$422.87K
65,389
0.0390%
$3.14M
−40.4%
Nichols Christian Todd
SVP, Chief Commercial Officer
$372.94K (2) scheduled
−$372.94K
102,193
0.0609%
$4.91M
+55.0%
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
$97.65K (1) scheduled
−$97.65K
223,422
0.1332%
$10.73M
+34.7%
POPS RICHARD F
Director and CEO, Alkermes plc
1,377,740
0.8212%
$66.15M
+16.8%
Jackson Blair Curtis
President & CEO, Alkermes plc
241,308
0.1438%
$11.59M
+52.9%
Brown Iain Michael
SVP, Chief Financial Officer
148,196
0.0883%
$7.11M
+27.4%
Cooke Shane
Director
106,679
0.0636%
$5.12M
+6.8%
MCKEON BRIAN P
Director
38,536
0.0230%
$1.85M
+38.7%
Wilson Frank Anders
Director
35,751
0.0213%
$1.72M
+43.0%
GAYNOR RICHARD
Director
35,751
0.0213%
$1.72M
+43.0%
LAURENCIN CATO T
Director
33,769
0.0201%
$1.62M
+70.5%
Wright Christopher I
Director
25,680
0.0153%
$1.23M
+78.1%
Lurker Nancy
Director
18,222
0.0109%
$874.84K
snyderman nancy lynn MD
Director
15,395
0.0092%
$739.11K
+231.9%
Parisi Samuel Joseph
VP, Finance (Interim PAO)
7,717
0.0046%
$370.49K
0.0%
Insider
Date
Role
Action
Shares
Price
Amount
Hopkinson Craig C.
1 Sep 2026
EVP R&D, Chief Medical Officer
Sold after exercise
9,000
$46.99
$422.87K

What was left out

Form 4 filings counted 3
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 1
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 5,000
History held since 7 Sep 2016